360 related articles for article (PubMed ID: 12841076)
1. The debate continues on OTC switches.
Giaquinta D
Manag Care Interface; 2003 Jun; 16(6):49-50. PubMed ID: 12841076
[No Abstract] [Full Text] [Related]
2. Escalating need for comparative analysis of drugs within a therapeutic class.
Giaquinta D
Manag Care Interface; 2003 Oct; 16(10):32-4. PubMed ID: 14606258
[No Abstract] [Full Text] [Related]
3. Plans continue to raise copayments.
Manag Care; 2005 Sep; 14(9):59. PubMed ID: 16238260
[No Abstract] [Full Text] [Related]
4. The Rx-to-OTC switch of Claritin, Allegra, and Zyrtec: an unprecedented FDA response to petitioners and the protection of public health.
Spencer HM
Am Univ Law Rev; 2002 Jun; 51(5):999-1050. PubMed ID: 12197546
[No Abstract] [Full Text] [Related]
5. Managed care cost containment involving prescription drugs. American Medical Association, Council on Ethical and Judicial Affairs.
Food Drug Law J; 1998; 53(1):25-34. PubMed ID: 11795334
[No Abstract] [Full Text] [Related]
6. Stats & facts. More consumer cost sharing in pharmacy benefit.
Manag Care Interface; 2002 Apr; 15(4):34-5. PubMed ID: 11979701
[No Abstract] [Full Text] [Related]
7. Direct-to-OTC marketing of drugs: possible approaches.
Mahinka SP; Bierman ME
Food Drug Law J; 1995; 50(1):49-63. PubMed ID: 10342985
[No Abstract] [Full Text] [Related]
8. Over-the-counter medications and self-care.
Lowe NK; Ryan-Wenger NM
Nurse Pract; 1999 Dec; 24(12):34-44. PubMed ID: 10635517
[TBL] [Abstract][Full Text] [Related]
9. Rx-to-OTC switch movement.
Rosenau PV
Med Care Rev; 1994; 51(4):429-66. PubMed ID: 10139533
[No Abstract] [Full Text] [Related]
10. Over-the-counter drugs as a new managed care benefit.
Scheur BS; Aaron RM
Med Interface; 1997 Feb; 10(2):88-94. PubMed ID: 10164797
[TBL] [Abstract][Full Text] [Related]
11. The effect of drug reimportation on managed care pharmacy.
Penna P
Manag Care Interface; 2003 Jul; 16(7):41-2. PubMed ID: 12908216
[No Abstract] [Full Text] [Related]
12. Should health plans offer an OTC drug benefit?
Navarro RP
Med Interface; 1996 Jun; 9(6):100-1, 108. PubMed ID: 10157922
[No Abstract] [Full Text] [Related]
13. [GMG proposal for non-prescription medications. Expensive cost savings].
MMW Fortschr Med; 2004 Aug; 146(31-32):48. PubMed ID: 15529713
[No Abstract] [Full Text] [Related]
14. Improving the PPI sample for prescription pharmaceuticals.
Kelly GG
Mon Labor Rev; 1997 Oct; 120(10):10-7. PubMed ID: 10176326
[No Abstract] [Full Text] [Related]
15. Rx-to-OTC switches: trends and factors underlying success.
Mahecha LA
Nat Rev Drug Discov; 2006 May; 5(5):380-5. PubMed ID: 16604099
[TBL] [Abstract][Full Text] [Related]
16. Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products.
Fed Regist; 1978 Sep; 43(190 Pt 2):45013-89. PubMed ID: 10316700
[No Abstract] [Full Text] [Related]
17. The Food and Drug Administration's over-the-counter drug review: why review OTC drugs?
Moxley JH; Yingling GL; Edwards CC
Fed Proc; 1973 Apr; 32(4):1435-7. PubMed ID: 4701750
[No Abstract] [Full Text] [Related]
18. Pharmaceuticals issue brief: managed care drug formularies: year end report-2003.
MacEachern L
Issue Brief Health Policy Track Serv; 2003 Dec; ():1-8. PubMed ID: 14969259
[TBL] [Abstract][Full Text] [Related]
19. Out-of-pocket payments in arthritis: spur to prudent purchasing or red herring?
Yelin E
Arthritis Rheum; 2008 Aug; 58(8):2225-7. PubMed ID: 18668560
[No Abstract] [Full Text] [Related]
20. Marketplace. Managed care plans try to cope as drug ads spur patient demand.
Moskowitz DB
Med Health; 1998 May; 52(20):suppl 1-2. PubMed ID: 10179010
[No Abstract] [Full Text] [Related]
[Next] [New Search]
